Background: Neutrophil-Lymphocyte Ratio (NLR) is known to be associated with anti-tumor response and tumor development through the process of angiogenesis and immunosuppression conditions. This study aims to analyze the strength of the association between NLR and therapy response of DLBCL-type non-Hodgkin's lymphoma (NHL) patients after undergoing 8 cycles of R-CHOP chemotherapy. Methods: This study used a retrospective cohort design with a total sampling of medical records of DLBCL-type NHL patients who received 8-cycle R-CHOP chemotherapy. Pre-chemotherapy NLR was calculated, and therapy response was assessed by clinical criteria. Results: Eighty-three samples were included, consisting of 57 male and 26 female subjects with an average age of 49 years and 16 patients in stage I, 24 patients in stage II and 43 people in stage III. Therapy response showed 48.2% complete response, 21.7% partial response, 7.2% stable disease and 22.9% progressive disease. Mean NLR in cycle 1 was 3.96 with the mean value of NLR in CR group 3.60, PR 4.287, SD 4.255 and PD 4.298. There was a negative association with moderate strength between NLR and post-chemotherapy therapy response (r=-0.498; p=0.000). Conclusion: There was a moderate negative association between NLR and therapy response of DLBCL-type NLH patients after 8 cycles of R-CHOP chemotherapy.
- Therapy response